Press releases and news
2023
Change in number of shares and votes in Camurus
Camurus to present at Jefferies 2023 Healthcare Conference New York
Camurus announces FDA approval of Brixadi™ for the treatment of moderate to severe opioid use disorder
Resolutions at the annual general meeting 2023 in Camurus
Camurus’ Interim Report January-March 2023
Camurus appoints Alberto Pedroncelli as Chief Medical Officer
Notice of annual general meeting 2023 in Camurus AB (publ)
Camurus Annual Report for 2022
Camurus’ Full Year Report 2022
Camurus withdraws variation application for CAM2038 to include chronic pain
2022
Change in number of shares and votes in Camurus
Camurus announces PDUFA date for Brixadi™ NDA for the treatment of opioid use disorder in the US
Camurus announces that Braeburn resubmits NDA for Brixadi™ in the US
Camurus to present at Jefferies 2022 Healthcare Conference London
Camurus’ Interim Report Third Quarter 2022
Camurus supports two Global Awareness Days for rare diseases
Camurus’ Nomination Committee appointed for the Annual General Meeting 2023
Camurus presenting five-year vision for growth and financial outlook at Capital Markets and R&D Day
Update of change in number of shares and votes in Camurus
Change in number of shares and votes in Camurus
Get the latest news from Camurus
Subscribe to receive latest news from Camurus directly to your email.